Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
17
×
life sciences
national blog main
17
×
san francisco blog main
boston blog main
boston top stories
clinical trials
san diego blog main
san diego top stories
san francisco top stories
national top stories
new york blog main
new york top stories
cancer
eli lilly
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
startups
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
medical device
seattle blog main
seattle top stories
texas blog main
texas top stories
cancer immunotherapy
deals
investing
pfizer
boehringer ingelheim
johnson & johnson
medicare
What
companies
17
×
new
life
bio
drug
ipo
science
roundup
week
biotech
disease
leading
medicines
raised
research
street
therapeutics
therapies
wall
approval
approved
awards
black
cancer
days
diamond
drugs
fda
hasn’t
haul
ipos
latest
led
merck
migraine
momentum
nash
neuro
news
pfizer
Language
unset
Current search:
biotech
×
companies
×
" national blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
4 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs
@xconomy.com
4 years ago
Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer
@xconomy.com
4 years ago
California Life Sciences Fueled by Education, Established Companies
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Connect Honors 7 New Products as ‘Most Innovative’ at Annual Awards
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Nominations Open for San Diego’s Inaugural Xconomy Awards
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M